Investigating the safety of AIT-102 in rats and dogs
Official title: TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102
Funded at Iit Research Institute · NIH-11191694 · Data updated 2026-11-12
This study is looking at how a drug called AIT-102 affects the health of rats and dogs to find out if it can harm specific organs and if those effects can be fixed, which will help make sure it's safe for people in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iit Research Institute NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2025 |
| Funding year | 2024 |
| Award (this year) | $568,068 |
| NIH project number | 75N91022D00016-0-759102400003-1 |
| Project ID | NIH-11191694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would be those involved in veterinary care or those with pets that may be affected by drug toxicity.
✕Less likely to help
Patients who do not have pets or are not involved in veterinary medicine may not receive any direct benefit from this research.
What this research studies
This research focuses on understanding the toxic effects of a drug called AIT-102 when administered to rats and dogs. The study aims to identify any organ-specific toxicities that may arise from the drug and evaluate whether these toxic effects can be reversed. By conducting these preclinical toxicology studies, the research seeks to provide critical safety data that could inform future clinical applications in humans. Patients may benefit indirectly from this research as it helps ensure the safety of new treatments before they are tested in human trials.
Why it matters
Potential benefit: If successful, this research could lead to safer drug therapies for patients by identifying and mitigating potential toxic effects before human trials.
How similar studies have gone: While toxicology studies in animals are common, the specific approach with AIT-102 is novel and has not been extensively tested in this context.
Where this research is happening
-
Iit Research Institute
Chicago, United States Active
Researchers
- Principal investigator: Mccormick, David — Iit Research Institute
- Study coordinator: Mccormick, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.